Breakdown | ||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
58.09B | 57.12B | 52.77B | 44.20B | 2.42B | Gross Profit |
37.89B | 37.23B | 34.97B | 30.01B | 1.41B | EBIT |
4.78B | 5.19B | 7.51B | 5.96B | -289.00M | EBITDA |
6.46B | 6.69B | 8.86B | 7.36B | -210.00M | Net Income Common Stockholders |
2.77B | 2.92B | 4.90B | 3.62B | -532.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
2.56B | 2.68B | 5.48B | 2.30B | 1.58B | Total Assets |
77.68B | 77.56B | 79.95B | 74.64B | 68.35B | Total Debt |
40.04B | 37.99B | 42.44B | 44.26B | 41.91B | Net Debt |
37.49B | 35.31B | 36.96B | 41.96B | 40.32B | Total Liabilities |
51.98B | 49.72B | 54.02B | 53.61B | 50.98B | Stockholders Equity |
25.70B | 27.84B | 25.93B | 21.03B | 17.37B |
Cash Flow | Free Cash Flow | |||
3.36B | 3.99B | 6.82B | 3.09B | 728.00M | Operating Cash Flow |
3.53B | 4.05B | 7.38B | 3.65B | 763.00M | Investing Cash Flow |
-584.00M | -511.00M | -981.00M | -1.55B | -33.02B | Financing Cash Flow |
-2.62B | -6.34B | -3.22B | -1.38B | 33.84B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | ¥56.20B | 20.25 | 3.74% | 7.66% | -35.51% | ||
80 Outperform | ¥41.55B | 11.67 | 4.29% | 10.22% | 2.21% | ||
78 Outperform | ¥57.59B | 19.95 | 4.82% | 10.90% | 40.18% | ||
74 Outperform | ¥60.90B | 13.21 | 3.55% | -2.99% | -27.98% | ||
72 Outperform | ¥39.03B | 21.00 | 2.99% | 26.09% | 46.10% | ||
66 Neutral | $4.50B | 12.28 | 5.32% | 248.52% | 4.13% | -12.36% | |
64 Neutral | ¥39.28B | 6.21 | 3.84% | 11.59% | 21.11% |
TRYT Inc. reported its consolidated financial results for the first quarter of 2025, showing an increase in revenue by 8.2% compared to the previous year, despite operating and net losses. The company anticipates a positive outlook for the fiscal year ending December 31, 2025, with expected revenue growth of 12.6% and significant improvements in profit margins, indicating strategic efforts to enhance financial performance.
TRYT Inc. emphasizes the importance of corporate governance as it navigates significant structural changes in the medical and welfare industries. The company adheres to all principles of the Corporate Governance Code and maintains a policy to protect minority shareholders by avoiding transactions with controlling shareholders unless deemed necessary and approved by the Board of Directors.
TRYT Inc. has announced details concerning its controlling shareholder, LIFE SCIENCE & DIGITAL HEALTH CO. LIMITED, which holds a 60% ownership stake. The company emphasizes that it generally avoids related party transactions unless deemed necessary and ensures such transactions are conducted under strict internal rules and board approval to protect minority shareholders.